January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 
January 18-22, 2016 | Town and Country Resort Hotel | SAN DIEGO, CA 

Pipeline Four Icon Pipeline Four Header  

Cambridge Healthtech Institute’s 2nd Annual
CHO Cell Culture
Enhancing Expression, Performance and Process
January 20-21, 2016

Advances in CHO cell culture technology continue to significantly improve biotherapeutic production. This achievement is due to progress in engineering stable and transient cell lines, enhancing cell culture conditions and performance, as well as optimizing process development. When all are accomplished, higher-production titers and better product quality result. The CHO Cell Culture conference gathers cell line engineers, cell culture specialists and bioprocess development managers to explore the latest data, tools and strategies for improving protein expression, production and product quality.

Preliminary Agenda


Exploiting the Proteomics Revolution in Biotechnology: From Disease and Antibody Targets to Optimizing Bioprocess Development

Deniz Baycin-Hizal, Ph.D., Scientist I, MedImmune

Multi-Omics Approach for Comparative Studies of Monoclonal Antibody-Producing CHO Cells

Lars Keld Nielsen, Ph.D., Chair & Professor, Biological Engineering, Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland

Designing CHO Cell Factories Using System Biology Models

Nathan E. Lewis, Ph.D., Assistant Professor, Department of Pediatrics, University of California, San Diego

Speed-to-Clinic Cell Line Development without Compromising on Cell Line Stability

Gang Chen, Ph.D., Executive Director, Protein Expression Sciences, Regeneron Pharmaceuticals, Inc.


Protein Expression Profiling of Different CHO Cell Lines: Striking Similarities

Denise Krawitz, Ph.D., Senior Manager, Analytical Operations, Genentech, Inc.

Metabolomics for Optimizing CHO Cell Culture Conditions

Zhongqi Zhang, Ph.D., Scientific Director, Amgen, Inc.


New Workflow Platform for High-Throughput Cell Line Development

Christian Bender, Ph.D., Computational Biologist, Global Drug Discovery, Global Biologics, Bayer HealthCare

Epigenetic Marks Enable Rejection of Unstable Chinese Hamster Ovary Cell Lines

Ulrich Goepfert, Ph.D., Principal Scientist, Cell Line & Molecular Development, Roche Innovation Center Penzberg

For questions about the meeting, please contact:  

Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5497
Email: mabrown@healthtech.com  

For partnering & sponsorship information, please contact:  

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470
Email: jgerardi@healthtech.com  

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470
Email: dinerstein@healthtech.com